Downstream Processing Market: Powering the Future of Biopharmaceutical Manufacturing
The global downstream processing market is undergoing a period of robust expansion, driven by the rapid growth of biologics, biosimilars, and next-generation therapeutics. Downstream processing refers to the collection of technologies and systems used to purify and separate biological products after production, transforming crude biological mixtures into high-purity, therapeutically active biopharmaceutical products. As biopharmaceutical manufacturers face increasingly strict purity and safety standards, the demand for advanced purification and separation technologies continues to climb, positioning this market as a critical pillar of modern drug development.
Market Size and Growth Trajectory
According to Fortune Business Insight, the global downstream processing market was valued at USD 34.84 billion in 2025 and is projected to grow from USD 37.26 billion in 2026 to USD 76.76 billion by 2034, reflecting a compound annual growth rate (CAGR) of 9.46% during the forecast period. This sustained growth underscores the irreplaceable role downstream processing plays in biopharmaceutical manufacturing, particularly as advanced therapeutics such as viral vectors, cell therapies, and mRNA vaccines increasingly rely on these technologies for quality assurance and scalable production.
According to Fortune Business Insight, North America dominated the global downstream processing market with a 42.16% share in 2025, maintaining its position as the leading region. The region’s dominance stems from a mature biopharmaceutical manufacturing ecosystem and the rapid expansion of contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs).
Key Market Drivers
A major driver propelling market growth is the exponential rise of biologics and biosimilars development worldwide. As disease burden increases globally, so does the production of biologics, which require multiple filtration and purification steps to meet stringent regulatory purity and safety standards. Key companies are actively expanding their manufacturing facilities to meet this demand, further fueling the need for downstream processing products and services. For instance, according to Fortune Business Insight, in November 2025, AstraZeneca invested USD 2.0 billion to expand its manufacturing footprint in Maryland, including the expansion of its biologics facility in Frederick and a new facility in Gaithersburg dedicated to developing and supplying innovative molecules for clinical trials.
Similarly, according to Fortune Business Insight, in September 2025, Eli Lilly constructed a USD 6.5 billion manufacturing facility in Texas, focused on producing small molecule medicines across therapeutic areas including cardiometabolic health, oncology, immunology, and neuroscience—further expanding the need for downstream purification processes.
Market Restraints and Challenges
Despite strong growth prospects, the market faces notable restraints. The high operational cost of advanced downstream processing equipment and consumables remains a significant barrier, particularly as biologics grow more complex and require increasingly sophisticated purification processes. This financial burden can create hesitancy among biopharmaceutical manufacturers when it comes to investing in new systems. According to Fortune Business Insight, in October 2025, 53Biologics reported scalability issues stemming from high resin costs and limited reusability in downstream processing.
Another challenge facing the industry is the incompatibility of certain downstream processing steps—such as viral inactivation, centrifugation, precipitation, and final sterilizing filtration—with continuous bioprocessing models. These steps often require large buffer volumes that don’t integrate naturally with constant-flow systems, forcing manufacturers into hybrid workflows that create synchronization issues and bottleneck risks.
Emerging Opportunities
Despite these challenges, the market presents lucrative growth opportunities, particularly in single-use technologies. As biologics diversify, manufacturers are increasingly shifting from stainless-steel systems to flexible, lower-risk single-use systems, including pre-packed columns and single-use viral clearance modules. According to Fortune Business Insight, in October 2021, Thermo Fisher Scientific Inc. launched the Thermo Scientific HyPeak chromatography system, a single-use chromatography solution for bioprocessing with applications in therapeutic protein and vaccine development.
Market Trends
A prominent trend shaping the industry is the shift from traditional batch purification methods toward continuous and intensified downstream processing, which enables higher throughput and reduced processing times. According to Fortune Business Insight, in May 2024, Sartorius AG collaborated with Sanofi to commercialize an end-to-end platform for downstream process intensification, offering a modular system that balances flexibility with standardization.
Segmentation Insights
By offering, the market is divided into products and services. According to Fortune Business Insight, the product segment dominated the market in 2025 due to its vast applications across every stage of downstream processing, while the services segment is expected to grow at a CAGR of 11.86% during the forecast period.
By technique, the market spans separation, filtration, concentration, viral inactivation, buffer exchange, and others. According to Fortune Business Insight, the filtration segment held the largest market share in 2025 and is projected to lead with a 35.0% share in 2026, owing to its extensive use across multiple stages of the purification workflow.
By application, the market includes mAbs and recombinant proteins, vaccines, cell and gene therapies, and blood and plasma products, among others. According to Fortune Business Insight, the mAbs and recombinant proteins segment accounted for the largest share in 2025 and is expected to lead with a 38.4% share in 2026, while the cell and gene therapy production segment is projected to grow at a robust CAGR of 12.18%.
By end user, pharmaceutical and biotechnology companies dominated the market in 2025 and are expected to maintain a 47.5% share in 2026, according to Fortune Business Insight, as these companies remain the primary manufacturers of biologics and heavily invest in internal downstream processing capabilities.
Regional Outlook
According to Fortune Business Insight, Europe is anticipated to grow at a CAGR of 9.10% and reach a market value of USD 9.94 billion by 2026, supported by high manufacturing capabilities for vaccines and other biologics. Within the region, the U.K. is expected to reach USD 2.14 billion, Germany USD 1.55 billion, and France USD 1.37 billion in 2026.
Meanwhile, Asia Pacific is projected to reach USD 8.73 billion by 2026, according to Fortune Business Insight, securing its position as the third-largest regional market, with India and China each expected to reach approximately USD 1.60 billion and USD 1.55 billion respectively.
Competitive Landscape
The global downstream processing market exhibits a semi-consolidated structure, with key players including Merck KGaA, Cytiva, Thermo Fisher Scientific Inc., Waters Corporation, METTLER TOLEDO, Sartorius AG, Repligen Corporation, ALFA LAVAL, PHYTON LTD, and WuXi Biologics. According to Fortune Business Insight, in October 2025, Merck KGaA acquired the chromatography business of JSR Life Sciences, expanding its downstream processing portfolio with advanced Protein A chromatography capabilities to support more efficient production of monoclonal antibodies.
Conclusion
The downstream processing market stands at the intersection of biopharmaceutical innovation and manufacturing excellence. As biologics, biosimilars, and advanced therapeutics continue to reshape global healthcare, the demand for efficient, scalable, and high-purity downstream processing solutions will only intensify. While high operational costs and integration challenges with continuous bioprocessing persist, emerging opportunities in single-use technologies and process intensification are expected to drive sustained innovation and investment across the industry through 2034.
What’s Driving Japan’s Market? Discover the Latest “Downstream Processing Market” Insights